Good news: Gilead is licensing remdesivir around the world
Remdesivir, the RNA polymerase inhibitor which received emergency use authorization from the US FDA after passing two randomized clinical trials for efficacy against COVID-19, will be available in more of the world due to a licensing deal between Gilead, the drug’s inventor, and five generic pharmaceutical companies in South Asia. As we’ve reported since February,